Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed Not applicable Interventional

Grow2Gether Pilot Study

NCT02037490
View directory record Official record
Conditions
Childhood Obesity
Interventions
Grow2Gether
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

NCT03321513
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maternal Nutrition Interventions in Uttar Pradesh, India

NCT03378141
View directory record Official record
Conditions
Anemia, Undernutrition, Underweight, Stunting, Maternal Malnutrition
Interventions
Maternal Nutrition Behavior change
Behavioral
Lead sponsor
International Food Policy Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology

NCT02860702
View directory record Official record
Conditions
Congenital Heart Defect
Interventions
Human Milk Derived Fortifier, Human/Bovine Milk
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
1 Day to 7 Days
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 21, 2026, 5:10 AM EDT
Recruiting No phase listed Observational

Evaluation of Children With Endocrine and Metabolic-Related Conditions

NCT02769975
View directory record Official record
Conditions
Adrenal Insufficiency, Growth Disorder, Endocrine Diseases, Metabolic Disease, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 100 Years
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB

NCT03673579
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
South Bend, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT02365662
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions
ABBV-221
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer

NCT00001269
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
IL-3
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures

NCT00404924
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
ZD6474 (vandetanib), Best Supportive Care
Drug · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Results available

Behavioral & Nutritional Treatment to Help CF Preschoolers Grow

NCT00241969
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Cystic Fibrosis
Interventions
Behavioral and Nutrition Treatment, Education and Attention Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 6 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

NCT00880282
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cixutumumab, temsirolimus, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sandostatin LAR® in Acromegaly

NCT01424241
View directory record Official record
Conditions
Acromegaly
Interventions
Sandostatin LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

NCT01868022
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3052230, paclitaxel, carboplatin, docetaxel, pemetrexed, cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 21, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

NCT00679029
View directory record Official record
Conditions
HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pegfilgrastim
Drug · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus

NCT00600795
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CSF collection
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 5:10 AM EDT
Withdrawn Phase 2 Interventional

A Study of Bevacizumab to Prevent Malignant Ascites

NCT00908219
View directory record Official record
Conditions
Malignant Ascites
Interventions
Bevacizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy

NCT06039319
View directory record Official record
Conditions
Fetal Growth Retardation, Fetal Growth Complications, Placental Insufficiency
Interventions
Physical activity
Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 21, 2026, 5:10 AM EDT
Completed No phase listed Observational

Growth of Airways and Lung Tissues in Premature and Healthy Infants

NCT00419588
View directory record Official record
Conditions
Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Asthma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 24 Months
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

NCT00283595
View directory record Official record
Conditions
Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
Interventions
Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877
View directory record Official record
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
114
States / cities
Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 5:10 AM EDT